Clinical Advances in Ovarian Cancer: Exploring the Expanding Role of PARP Inhibitors in the Treatment Paradigm

To receive up to 1.0 CME/CE credit please complete the evaluation and request form here: https://www.ceconcepts.com/ovarian-gr-podcast

Learning Objectives

• Review recent updates to national guideline recommendations in ovarian cancer treatment and testing and discuss health equity issues that may hinder ovarian cancer patients from receiving the current standard of care.
• Appraise landmark and emerging safety and efficacy data with PARP inhibitors in the treatment of ovarian cancer, with a focus on most recent recommendations and rationale for the use of PARP inhibitors in the first-line maintenance setting.
• Analyze the unique toxicity profiles among PARP inhibitor therapies and important considerations for both monitoring and managing adverse events.
• Use an interactive, multi-disciplinary approach to discuss challenging cases regarding the appropriate selection of treatment based on clinical data and guidelines, the use of predictive biomarkers, the management of adverse events, and strategies to mitigate modifiable healthcare disparities in ovarian cancer patients.

Presented by Creative Educational Concepts, LLC.

Supported through an independent educational grant from GSK.